ZA200304664B - Lentiviral vector-mediated gene transfer and uses thereof - Google Patents
Lentiviral vector-mediated gene transfer and uses thereof Download PDFInfo
- Publication number
- ZA200304664B ZA200304664B ZA200304664A ZA200304664A ZA200304664B ZA 200304664 B ZA200304664 B ZA 200304664B ZA 200304664 A ZA200304664 A ZA 200304664A ZA 200304664 A ZA200304664 A ZA 200304664A ZA 200304664 B ZA200304664 B ZA 200304664B
- Authority
- ZA
- South Africa
- Prior art keywords
- gene
- cells
- lentiviral
- timp
- endostatin
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 147
- 239000013598 vector Substances 0.000 title claims description 99
- 238000012546 transfer Methods 0.000 title description 30
- 230000001404 mediated effect Effects 0.000 title description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 31
- 108010079505 Endostatins Proteins 0.000 claims description 28
- 108010079709 Angiostatins Proteins 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 230000033115 angiogenesis Effects 0.000 claims description 23
- 206010029113 Neovascularisation Diseases 0.000 claims description 22
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 22
- 230000006907 apoptotic process Effects 0.000 claims description 18
- 230000004663 cell proliferation Effects 0.000 claims description 15
- 108700025701 Retinoblastoma Genes Proteins 0.000 claims description 14
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims description 14
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 13
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 claims description 13
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims description 13
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 13
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims description 13
- 208000022873 Ocular disease Diseases 0.000 claims description 12
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 claims description 12
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 12
- 102100024289 Metalloproteinase inhibitor 4 Human genes 0.000 claims description 11
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 11
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 11
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 11
- 108700000711 bcl-X Proteins 0.000 claims description 11
- 102000055104 bcl-X Human genes 0.000 claims description 11
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 10
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 10
- 208000002780 macular degeneration Diseases 0.000 claims description 10
- 230000002062 proliferating effect Effects 0.000 claims description 10
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 8
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 7
- 108020001507 fusion proteins Proteins 0.000 claims description 7
- 102000037865 fusion proteins Human genes 0.000 claims description 7
- 230000002463 transducing effect Effects 0.000 claims description 7
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 6
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 claims description 6
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 claims description 6
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 5
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 claims description 5
- 102400001051 Restin Human genes 0.000 claims description 5
- 101800000689 Restin Proteins 0.000 claims description 5
- 102000006992 Interferon-alpha Human genes 0.000 claims description 4
- 108010047761 Interferon-alpha Proteins 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 102100034629 Hemopexin Human genes 0.000 claims description 3
- 108010026027 Hemopexin Proteins 0.000 claims description 3
- 108010029485 Protein Isoforms Proteins 0.000 claims description 3
- 102000001708 Protein Isoforms Human genes 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 claims description 2
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 claims description 2
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 claims description 2
- 108050006579 Metalloproteinase inhibitor 4 Proteins 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 102400001047 Endostatin Human genes 0.000 claims 4
- 102400000068 Angiostatin Human genes 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 claims 1
- 208000036866 Vitreoretinopathy Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 99
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 23
- 238000000034 method Methods 0.000 description 23
- 102000012936 Angiostatins Human genes 0.000 description 22
- 230000002401 inhibitory effect Effects 0.000 description 22
- 238000001727 in vivo Methods 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 238000010361 transduction Methods 0.000 description 18
- 230000026683 transduction Effects 0.000 description 17
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 16
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 16
- 230000004927 fusion Effects 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 210000004087 cornea Anatomy 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 230000002207 retinal effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 11
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 241000713666 Lentivirus Species 0.000 description 10
- 210000002889 endothelial cell Anatomy 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 10
- 108010008883 tissue inhibitor of metalloproteinase-4 Proteins 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 230000000964 angiostatic effect Effects 0.000 description 9
- 108700000707 bcl-2-Associated X Proteins 0.000 description 9
- 102000055102 bcl-2-Associated X Human genes 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 210000001525 retina Anatomy 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 8
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 8
- 101100381649 Mus musculus Bik gene Proteins 0.000 description 8
- 102000005406 Tissue Inhibitor of Metalloproteinase-3 Human genes 0.000 description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- 230000032823 cell division Effects 0.000 description 8
- 210000002744 extracellular matrix Anatomy 0.000 description 8
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 7
- 206010038848 Retinal detachment Diseases 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 108010012236 Chemokines Proteins 0.000 description 6
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 6
- 201000000582 Retinoblastoma Diseases 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 230000004264 retinal detachment Effects 0.000 description 6
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 6
- 102100021971 Bcl-2-interacting killer Human genes 0.000 description 5
- 201000004569 Blindness Diseases 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 101000970576 Homo sapiens Bcl-2-interacting killer Proteins 0.000 description 5
- 101000987578 Homo sapiens Peripherin Proteins 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 5
- 108010003081 Peripherins Proteins 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000003511 endothelial effect Effects 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000001177 retroviral effect Effects 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 4
- 208000002177 Cataract Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003782 apoptosis assay Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 210000000695 crystalline len Anatomy 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000005522 programmed cell death Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000000790 retinal pigment Substances 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 3
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 description 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 3
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000009400 cancer invasion Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000003399 chemotactic effect Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 230000007159 enucleation Effects 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229960000707 tobramycin Drugs 0.000 description 3
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- 230000004862 vasculogenesis Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108050006947 CXC Chemokine Proteins 0.000 description 2
- 102000019388 CXC chemokine Human genes 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 206010055665 Corneal neovascularisation Diseases 0.000 description 2
- 101710157567 Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 2
- 101001007419 Homo sapiens Lens epithelial cell protein LEP503 Proteins 0.000 description 2
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 2
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 206010036346 Posterior capsule opacification Diseases 0.000 description 2
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- 108700041737 bcl-2 Genes Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 201000000255 cycloplegia Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000002555 descemet membrane Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000005081 epithelial layer Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 102000055233 human LENEP Human genes 0.000 description 2
- 102000052045 human PRPH Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000001542 lens epithelial cell Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000002577 ophthalmoscopy Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229960003981 proparacaine Drugs 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- RVNZEJNWTUDQSC-JOCHJYFZSA-N (2r)-n-(6-aminohexyl)-1-tridecanoylpyrrolidine-2-carboxamide Chemical compound CCCCCCCCCCCCC(=O)N1CCC[C@@H]1C(=O)NCCCCCCN RVNZEJNWTUDQSC-JOCHJYFZSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- LFTRJWKKLPVMNE-RCBQFDQVSA-N 2-[[(2s)-2-[[2-[[(2s)-1-[(2s)-2-amino-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-methylbutanoyl]amino]acetic acid Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O LFTRJWKKLPVMNE-RCBQFDQVSA-N 0.000 description 1
- YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 102100034594 Angiopoietin-1 Human genes 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 101150013616 BHRF1 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101150079123 Bad gene Proteins 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 102100027453 Bcl2-associated agonist of cell death Human genes 0.000 description 1
- 101710081085 Bcl2-associated agonist of cell death Proteins 0.000 description 1
- 101150098639 Bik gene Proteins 0.000 description 1
- 101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 229940122097 Collagenase inhibitor Drugs 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000037057 G1 phase arrest Effects 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 101100122503 Human herpesvirus 6A (strain Uganda-1102) gN gene Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- 101150088608 Kdr gene Proteins 0.000 description 1
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 108050006602 Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 108050006600 Metalloproteinase inhibitor 3 Proteins 0.000 description 1
- 101500025937 Mus musculus Angiostatin Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 101710149086 Nuclease S1 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101800000990 PEX Proteins 0.000 description 1
- 102000004590 Peripherins Human genes 0.000 description 1
- 102100035153 Phosphate-regulating neutral endopeptidase PHEX Human genes 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091006627 SLC12A9 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 101150023355 Timp4 gene Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241001255741 Vanna Species 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 101150031722 XVIII gene Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000002095 anti-migrative effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 108010007734 bcl-Associated Death Protein Proteins 0.000 description 1
- 102000007348 bcl-Associated Death Protein Human genes 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229940087828 buprenex Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000003366 colagenolytic effect Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002442 collagenase inhibitor Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 210000003683 corneal stroma Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 230000009762 endothelial cell differentiation Effects 0.000 description 1
- 210000000871 endothelium corneal Anatomy 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001497 fibrovascular Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 102000050995 human FLT1 Human genes 0.000 description 1
- 102000053150 human MMP2 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000021616 negative regulation of cell division Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 108700042657 p16 Genes Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000005047 peripherin Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000030786 positive chemotaxis Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 108091008601 sVEGFR Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000012256 transgenic experiment Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108010054022 valyl-prolyl-glycyl-valyl-glycine Proteins 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25670100P | 2000-12-19 | 2000-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200304664B true ZA200304664B (en) | 2007-02-28 |
Family
ID=22973247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200304664A ZA200304664B (en) | 2000-12-19 | 2003-06-17 | Lentiviral vector-mediated gene transfer and uses thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20020114783A1 (zh) |
| EP (2) | EP1343532B1 (zh) |
| JP (2) | JP4280496B2 (zh) |
| KR (3) | KR20080080684A (zh) |
| CN (2) | CN101732731B (zh) |
| AU (2) | AU2002234053B2 (zh) |
| CA (1) | CA2432301C (zh) |
| DK (2) | DK1343532T3 (zh) |
| ES (2) | ES2422301T3 (zh) |
| IL (2) | IL156427A0 (zh) |
| NZ (1) | NZ526558A (zh) |
| PT (2) | PT2301583E (zh) |
| RU (1) | RU2288742C2 (zh) |
| WO (1) | WO2002049677A1 (zh) |
| ZA (1) | ZA200304664B (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080080684A (ko) * | 2000-12-19 | 2008-09-04 | 리서치 디벨럽먼트 파운데이션 | 렌티바이러스 벡터-매개된 유전자 전달 및 이를 위한 조성물 |
| US7122181B2 (en) * | 2000-12-19 | 2006-10-17 | Research Development Foundation | Lentiviral vector-mediated gene transfer and uses thereof |
| JP4689144B2 (ja) | 2001-02-22 | 2011-05-25 | ノバルティス アーゲー | 眼球血管新生を処置するための方法 |
| AU2003277910A1 (en) * | 2002-09-27 | 2004-04-19 | Novartis Ag | Ocular gene therapy |
| US7601341B2 (en) * | 2003-06-05 | 2009-10-13 | Research Development Foundation | Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis |
| US20060259997A1 (en) * | 2003-08-29 | 2006-11-16 | Shinji Iijima | Method of constructing transgenic bird using lentivirus vector and transgenic bird obtained thereby |
| EP1881849A2 (en) * | 2005-04-29 | 2008-01-30 | Research Development Foundation | Vascular targeting of ocular neovascularization |
| WO2008044339A1 (fr) * | 2006-10-13 | 2008-04-17 | Aqumen Biopharmaceuticals K.K. | Agent thérapeutique/de prévention contenant un composé de statine, utilisé pour une maladie intraoculaire |
| CN101870734B (zh) * | 2010-05-25 | 2012-06-20 | 北京大学 | 一种抑制新生血管生成的融合多肽及其编码基因与应用 |
| RU2444734C1 (ru) * | 2010-11-03 | 2012-03-10 | ФГУ Ростовский НИИ акушерства и педиатрии Министерства по здравоохранению и социальному развитию РФ | Способ прогнозирования невынашивания беременности ранних сроков инфекционного генеза |
| CA2940765A1 (en) | 2014-02-25 | 2015-09-03 | Research Development Foundation | Sty peptides for inhibition of angiogenesis |
| US11206977B2 (en) | 2014-11-09 | 2021-12-28 | The Trustees Of The University Of Pennyslvania | Vision test for determining retinal disease progression |
| GB2547179A (en) * | 2015-10-26 | 2017-08-16 | Quethera Ltd | Genetic construct |
| CN111398595A (zh) * | 2020-02-17 | 2020-07-10 | 天津医科大学眼科医院 | 一种血浆小细胞外囊泡中的蛋白质tnfaip8的应用和检测方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5969120A (en) * | 1993-09-03 | 1999-10-19 | Research Development Foundation | Mutants of the RB and P53 genes |
| US5871723A (en) * | 1995-06-06 | 1999-02-16 | The Regent Of The University Of Michigan | CXC chemokines as regulators of angiogenesis |
| US5686414A (en) * | 1995-11-14 | 1997-11-11 | Xoma Corporation | Methods of treating conditions associated with corneal transplantation |
| ES2246513T3 (es) * | 1996-05-03 | 2006-02-16 | Abbott Laboratories | Nuevos peptidos anti-angiogenicos, polinucleotidos que los codifican y procedimientos de inhibicion de la angiogenesis. |
| US6004798A (en) * | 1997-05-14 | 1999-12-21 | University Of Southern California | Retroviral envelopes having modified hypervariable polyproline regions |
| JPH1180024A (ja) * | 1997-09-12 | 1999-03-23 | Toagosei Co Ltd | 角膜血管新生阻害剤 |
| CA2367375A1 (en) * | 1999-03-15 | 2000-09-21 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| KR20080080684A (ko) * | 2000-12-19 | 2008-09-04 | 리서치 디벨럽먼트 파운데이션 | 렌티바이러스 벡터-매개된 유전자 전달 및 이를 위한 조성물 |
-
2001
- 2001-12-18 KR KR1020087020793A patent/KR20080080684A/ko not_active Application Discontinuation
- 2001-12-18 CA CA2432301A patent/CA2432301C/en not_active Expired - Lifetime
- 2001-12-18 RU RU2003122214/14A patent/RU2288742C2/ru not_active IP Right Cessation
- 2001-12-18 EP EP01985065.0A patent/EP1343532B1/en not_active Expired - Lifetime
- 2001-12-18 KR KR1020097027248A patent/KR101026078B1/ko active IP Right Grant
- 2001-12-18 AU AU2002234053A patent/AU2002234053B2/en not_active Ceased
- 2001-12-18 IL IL15642701A patent/IL156427A0/xx unknown
- 2001-12-18 PT PT101771855T patent/PT2301583E/pt unknown
- 2001-12-18 DK DK01985065.0T patent/DK1343532T3/da active
- 2001-12-18 AU AU3405302A patent/AU3405302A/xx active Pending
- 2001-12-18 ES ES01985065T patent/ES2422301T3/es not_active Expired - Lifetime
- 2001-12-18 DK DK10177185.5T patent/DK2301583T3/da active
- 2001-12-18 JP JP2002551014A patent/JP4280496B2/ja not_active Expired - Fee Related
- 2001-12-18 CN CN200910266851XA patent/CN101732731B/zh not_active Expired - Fee Related
- 2001-12-18 CN CN01822491A patent/CN100591359C/zh not_active Expired - Fee Related
- 2001-12-18 EP EP10177185A patent/EP2301583B1/en not_active Expired - Lifetime
- 2001-12-18 KR KR10-2003-7008168A patent/KR20030075152A/ko not_active Application Discontinuation
- 2001-12-18 NZ NZ526558A patent/NZ526558A/en not_active IP Right Cessation
- 2001-12-18 PT PT1985065T patent/PT1343532E/pt unknown
- 2001-12-18 ES ES10177185T patent/ES2393717T3/es not_active Expired - Lifetime
- 2001-12-18 WO PCT/US2001/049241 patent/WO2002049677A1/en active IP Right Grant
- 2001-12-19 US US10/025,264 patent/US20020114783A1/en not_active Abandoned
-
2003
- 2003-06-12 IL IL156427A patent/IL156427A/en active IP Right Grant
- 2003-06-17 ZA ZA200304664A patent/ZA200304664B/en unknown
-
2009
- 2009-01-28 JP JP2009016488A patent/JP2009137998A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009137998A (ja) | 2009-06-25 |
| JP4280496B2 (ja) | 2009-06-17 |
| EP1343532A4 (en) | 2006-03-15 |
| US20020114783A1 (en) | 2002-08-22 |
| CN100591359C (zh) | 2010-02-24 |
| CN101732731A (zh) | 2010-06-16 |
| JP2004520307A (ja) | 2004-07-08 |
| KR20030075152A (ko) | 2003-09-22 |
| DK2301583T3 (da) | 2012-12-10 |
| EP1343532B1 (en) | 2013-04-24 |
| EP2301583A1 (en) | 2011-03-30 |
| AU3405302A (en) | 2002-07-01 |
| PT2301583E (pt) | 2012-12-06 |
| RU2288742C2 (ru) | 2006-12-10 |
| CA2432301C (en) | 2013-06-04 |
| CA2432301A1 (en) | 2002-06-27 |
| PT1343532E (pt) | 2013-07-29 |
| WO2002049677A1 (en) | 2002-06-27 |
| DK1343532T3 (da) | 2013-07-29 |
| CN1487841A (zh) | 2004-04-07 |
| CN101732731B (zh) | 2013-04-10 |
| NZ526558A (en) | 2004-06-25 |
| ES2393717T3 (es) | 2012-12-27 |
| KR20100011994A (ko) | 2010-02-03 |
| KR20080080684A (ko) | 2008-09-04 |
| IL156427A0 (en) | 2004-01-04 |
| IL156427A (en) | 2011-06-30 |
| EP1343532A1 (en) | 2003-09-17 |
| KR101026078B1 (ko) | 2011-03-31 |
| ES2422301T3 (es) | 2013-09-10 |
| AU2002234053B2 (en) | 2004-07-15 |
| EP2301583B1 (en) | 2012-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7122181B2 (en) | Lentiviral vector-mediated gene transfer and uses thereof | |
| JP2009137998A (ja) | レンチウイルス・ベクター媒介遺伝子導入及びその使用 | |
| JP4418536B2 (ja) | レトロウイルスベクター | |
| JP4959547B2 (ja) | Ｓｉｖ−ｐｅｄｆベクターを用いた眼組織細胞におけるアポトーシス変性を伴う疾患の治療薬 | |
| US20070072816A1 (en) | Methods for inhibiting angiogenesis | |
| Stout | Gene transfer for the treatment of neovascular ocular disease (an American Ophthalmological Society thesis) | |
| CHO et al. | Replication of HIV type 1 in rabbit cell lines is not limited by deficiencies in tat, rev, or long terminal repeat function | |
| Hanawa et al. | 93. Diminished Mobilization of Self-Inactivating (SIN) Lentiviral Vectors Containing Globin Regulatory Elements Compared to Those Containing a Retroviral Long Terminal Repeat | |
| Joseph | Non-integrating integrase and long terminal repeat attachment site mutant HIV-1-derived lentiviral vectors |